Nothing Special   »   [go: up one dir, main page]

MX351247B - Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. - Google Patents

Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Info

Publication number
MX351247B
MX351247B MX2012011371A MX2012011371A MX351247B MX 351247 B MX351247 B MX 351247B MX 2012011371 A MX2012011371 A MX 2012011371A MX 2012011371 A MX2012011371 A MX 2012011371A MX 351247 B MX351247 B MX 351247B
Authority
MX
Mexico
Prior art keywords
fusions
mycobacterium tuberculosis
immunogenic compositions
tuberculosis polypeptides
compositions
Prior art date
Application number
MX2012011371A
Other languages
English (en)
Inventor
Steven G Reed
Rhea N Coler
Gregory C Ireton
Sylvie Bertholet
Original Assignee
Infectious Disease Res Institute Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Institute Star filed Critical Infectious Disease Res Institute Star
Publication of MX351247B publication Critical patent/MX351247B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

La presente invención se refiere a una composición, caracterizada porque comprende un inmunoestimulante y una combinación de dos o más antígenos de Mycobacterium tuberculosis, en donde la combinación comprende un antígeno que tiene una secuencia que tiene por lo menos 90% de identidad (SEQ ID NO: 41) y un antígeno que tiene una secuencia que tiene por lo menos 905% de identidad a (SEQ ID NO: 46). Un polipéptido de fusión aislado, caracterizado porque comprende una combinación de dos o más antígenos de Mycobacterium tuberculosis covalentemente enlazados, en donde la combinación comprende un antígeno que tiene una secuencia que tiene por lo menos 90% de identidad y sus usos para estimular una respuesta inmune protectora.
MX2012011371A 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. MX351247B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91016907P 2007-04-04 2007-04-04
PCT/US2008/059500 WO2008124647A2 (en) 2007-04-04 2008-04-04 Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Publications (1)

Publication Number Publication Date
MX351247B true MX351247B (es) 2017-10-05

Family

ID=39620241

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009010800A MX2009010800A (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
MX2012011371A MX351247B (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009010800A MX2009010800A (es) 2007-04-04 2008-04-04 Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Country Status (11)

Country Link
US (5) US8486414B2 (es)
EP (2) EP2136836B8 (es)
JP (3) JP5378350B2 (es)
CN (2) CN101687027B (es)
BR (1) BRPI0809926B8 (es)
DK (1) DK2136836T3 (es)
ES (1) ES2621211T3 (es)
MX (2) MX2009010800A (es)
PL (1) PL2136836T3 (es)
WO (1) WO2008124647A2 (es)
ZA (1) ZA200907316B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397855A3 (en) * 2006-03-14 2012-03-14 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US9173930B2 (en) * 2009-11-20 2015-11-03 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN102586139B (zh) * 2012-01-20 2013-03-20 广东本科生物工程股份有限公司 一种高产ad/add的菌株及高效生产ad/add的方法
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
EP3415919B1 (en) 2012-02-07 2020-07-29 Intuitive Biosciences Inc. Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
US10048561B2 (en) 2013-02-21 2018-08-14 View, Inc. Control method for tintable windows
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
MX2015001557A (es) * 2012-08-03 2015-10-08 Infectious Disease Res Inst Composiciones y metodos para tratar una infeccion activa por mycobacterium tuberculosis.
CN102899334B (zh) * 2012-10-29 2015-02-25 英诺特(唐山)生物技术有限公司 一种结核分枝杆菌重组蛋白质及其制备方法
EP2968496A4 (en) 2013-03-15 2016-07-27 Univ Pennsylvania SYNTHESIS IMMUNOGENS FOR PROPHYLAXIS OR TREATMENT OF TUBERCULOSIS
CN104237509B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
CN104237508B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
JP6554095B2 (ja) * 2013-06-25 2019-07-31 アエラス グローバル ティービー ワクチン ファウンデーション 結核組成物及びそれを使用する方法
US10226522B2 (en) * 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
CN103698531B (zh) * 2013-11-25 2015-10-14 广东体必康生物科技有限公司 Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途
EA201691348A1 (ru) * 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
BR112016015936A2 (pt) * 2014-01-09 2017-09-19 Transgene Sa Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
KR101477795B1 (ko) * 2014-04-23 2015-01-02 건국대학교 산학협력단 Adk 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
SG11201704766UA (en) * 2014-12-10 2017-07-28 Konkuk Univ Glocal Industry-Academic Collaboration Found Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
EP3292765A4 (en) * 2015-04-03 2019-03-13 Konkuk University Glocal Industry-Academic Collaboration Foundation ANTIBACTERIAL COMPOSITION FOR THE CONTROL OF CARBAPENEMA-RESISTANT GRAM NEGATIVE BACTERIA COMPRISING AN ADK PROTEIN AS ACTIVE INGREDIENT
CN106645733A (zh) * 2015-07-16 2017-05-10 广东体必康生物科技有限公司 用于特异性检测结核分枝杆菌感染的蛋白
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
KR20190009308A (ko) * 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
BR112018074352B1 (pt) 2016-06-01 2021-11-30 Infectious Disease Research Institute Partículas de nanoalume contendo um agente de dimensionamento
CN109890411A (zh) 2016-06-16 2019-06-14 国际艾滋病疫苗行动组织公司 结核病组合物和治疗或预防结核病的方法
EP3474889A4 (en) 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS AS VACCINE AGAINST TUBERCULOSIS
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN107817228B (zh) * 2017-06-30 2022-06-14 四川农业大学 对E.coli O157:H7免酶及免荧光标记的检测方法
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
EP3697806A4 (en) * 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. TUBERCULOSIS ANTIGEN CASSETTES
US20200385818A1 (en) * 2017-12-22 2020-12-10 Massachusetts Eye And Ear Infirmary Comprehensive Microbial Panel for Molecular Diagnosis of Eye Infections
MX2020011298A (es) * 2018-04-26 2021-01-29 Childrens Nat Medical Ct Composiciones de antígeno micobacteriano y métodos de uso.
CN108411030B (zh) * 2018-05-25 2021-05-14 兰州大学 引物对及包含其的试剂盒、用途和检测蒺藜苜蓿生态型a17和r108的方法
CN108948175B (zh) * 2018-07-23 2020-11-20 首都医科大学附属北京胸科医院 与人类蛋白smad2相互作用的结核蛋白及其应用
JP2021535930A (ja) * 2018-09-17 2021-12-23 キュラティス インコーポレイティッド Stingアゴニストを含む抗原性補強剤及びワクチン組成物
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
WO2020222559A1 (ko) * 2019-05-02 2020-11-05 주식회사 엘베이스 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CN111286551A (zh) * 2020-01-04 2020-06-16 昆明理工大学 结核分枝杆菌的快速检测引物、试剂盒及其使用方法
AU2021241355A1 (en) 2020-03-23 2022-10-13 Hdt Bio Corp. Compositions and methods for delivery of RNA
US20240050561A1 (en) 2020-12-23 2024-02-15 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
CN113121703B (zh) * 2021-03-03 2023-04-25 上海晶诺生物科技有限公司 一种具有结核杆菌免疫原性的融合蛋白及其应用
CN114150006B (zh) * 2021-11-29 2023-07-25 中国农业科学院植物保护研究所 一种可提高米尔贝霉素产量的基因簇、重组菌及其制备方法与应用
CN116262794B (zh) * 2021-12-13 2024-09-13 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116041454B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因、应用
NL2036756B1 (en) * 2024-01-05 2024-08-29 Univ Shihezi Fluorescent pcr method for detecting listeria monocytogenes and mycobacterium tuberculosis in milk

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4761180A (en) 1986-08-27 1988-08-02 Hewlett-Packard Company Dyes containing tetramethylammonium cation for ink-jet printing inks
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) * 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1484405A1 (en) 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20020081579A1 (en) 1998-02-13 2002-06-27 Jane E. R. Potter Method for the isolation of novel antigens
NZ507378A (en) 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
NZ506603A (en) 1998-04-09 2002-10-25 Smithkline Beecham Biolog S Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU2003224313A1 (en) * 2002-04-27 2003-11-17 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2006026404A2 (en) * 2004-08-26 2006-03-09 Sequella, Inc. Assay for detecting tuberculosis in nonhuman primates
WO2006026464A2 (en) * 2004-08-27 2006-03-09 Davidsen Kevin P Handclapping aid
KR101035053B1 (ko) * 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
EP3795173A1 (en) * 2006-09-26 2021-03-24 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.

Also Published As

Publication number Publication date
WO2008124647A2 (en) 2008-10-16
CN101687027B (zh) 2015-01-28
PL2136836T3 (pl) 2017-07-31
EP3199176B1 (en) 2020-02-19
ES2621211T3 (es) 2017-07-03
US20220017578A1 (en) 2022-01-20
US8486414B2 (en) 2013-07-16
US11091521B2 (en) 2021-08-17
JP5922074B2 (ja) 2016-05-24
US20100129391A1 (en) 2010-05-27
JP2016145209A (ja) 2016-08-12
US20240140997A1 (en) 2024-05-02
ZA200907316B (en) 2013-03-27
US11897922B2 (en) 2024-02-13
JP2014058520A (ja) 2014-04-03
EP2136836B8 (en) 2017-04-12
JP2010524854A (ja) 2010-07-22
US9822152B2 (en) 2017-11-21
BRPI0809926A2 (pt) 2014-10-07
BRPI0809926B8 (pt) 2021-05-25
EP2136836A2 (en) 2009-12-30
US20130209500A1 (en) 2013-08-15
BRPI0809926B1 (pt) 2020-09-29
DK2136836T3 (en) 2017-04-10
CN104815324A (zh) 2015-08-05
MX2009010800A (es) 2010-01-29
JP5378350B2 (ja) 2013-12-25
EP2136836B1 (en) 2017-01-04
WO2008124647A3 (en) 2009-04-02
US20180170975A1 (en) 2018-06-21
CN101687027A (zh) 2010-03-31
EP3199176A1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
SG158145A1 (en) Vaccines against chlamydial infection
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
WO2006082406A3 (en) Human antibodies and proteins
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
DK2054431T3 (da) Konformere af bakterielle adhæsiner
MXPA06010469A (es) Proteina recombinante portadora de epitopos del virus de papiloma humano insertados en una proteina adenilato ciclasa o en un fragmento de ella y sus usos terapeuticos.
MX2010005589A (es) Composicion para el cuidado personal.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
CL2007003190A1 (es) Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras.
WO2016161415A3 (en) Tnfrsf14/ hvem proteins and methods of use thereof
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
MX2010003220A (es) Proteinas inmunogenicas de membrana exterior derivada de genoma de leptospira y composiciones y metodos basados en las mismas.